Research Article 
EGFR and K-Ras Gene Mutations in the Diagnosis of Non-Small Cell Lung Cancer and their Pathological Correlation
Zhenhua Wu, Waresijiang Yibulayin, Dan He, Keming Xu, Xiayimaierdan Yibulayin, Lei Ma and Xiaohong Sun
International Journal of Pharmacology, 2024, 20(5), 874-882.
Abstract
Background and Objective: The incidence of Non-Small Cell Lung Cancer (NSCLC) has been steadily increasing in recent years and its subtle clinical manifestations in the early stages lead to poor patient prognosis. Gene mutations are associated with the occurrence and progression of NSCLC. This study aimed to investigate the value of EGFR and K-ras gene mutations in the diagnosis of NSCLC and analyze their correlation with pathological characteristics of patients. Materials and Methods: A total of 180 patients, 90 were taken as control while other 90 patients diagnosed with NSCLC from August 2020 to January 2023 were selected as the study group. The detection rates of EGFR and K-ras gene mutations were compared between the two groups. The main phenotypes of EGFR and K-ras gene mutations in the study group were analyzed and the correlation between the gene mutations and the pathological characteristics of the patients (degree of differentiation, presence or absence of lymph node metastases, histological typing, patient gender, etc.) were analyzed. Results: The gene mutation rates of EGFR and K-ras were significantly higher in the study group than in the control group. In 90 patients with NSCLC, the mutation rate of EGFR gene mutations was 48.89%, while the mutation rate of K-ras gene mutations was 12.22%. The EGFR gene mutation rate was significantly higher in adenocarcinoma than in squamous cell carcinoma (p<0.05) and the degree of differentiation was significantly correlated with the EGFR gene mutation rate (p<0.05). Conclusion: The gene mutation rates of EGFR and K-ras in NSCLC patients were significantly higher than those of benign lung lesions. There was a certain correlation between the EGFR gene mutation rate and the pathological characteristics of the patients, which should be verified in further studies.
ASCI-ID: 23-2038
Similar Articles
The Pharmacokinetics of Mitomycin C in the Mitomycin C, Ifosfamide and Cisplatin (MIC) Regimen
International Journal of Pharmacology, 2006, 2(3), 293-297.
miR-193a-3p Overexpression Inhibits Proliferation and Enhances Paclitaxel Chemosensitivity in Human Non-Small-Cell Lung Cancer CellsInternational Journal of Pharmacology, 2021, 17(8), 541-548.